An Iranian brand of deferasirox, Osveral, may be as effective as Exjade for reducing iron overload among patients with major beta thalassemia, according to research published in the Caspian Journal of Internal Medicine.

Major beta thalassemia, a heritable hemolytic anemia characterized by ineffective erythropoiesis and hemolysis, is generally treated with blood transfusions and iron chelation. Both treatments are considered necessary for reducing serum iron overload, which may damage organs and cause mortality.

Standard iron chelation has included deferasirox for the past decade in the United States. Previously published research has, furthermore, shown that deferasirox is both safe and effective in patients older than 2 years.

Continue Reading

There are, however, several brand names of deferasirox available. For this study, researchers aimed to determine whether Osveral, an Iranian brand of deferasirox, is as equally effective as is Exjade, which was marketed by Novartis in the US, among patients with major beta thalassemia.

Overall, of 92 patients assessed for study eligibility, 80 (40 to the Osveral group and 40 to the Exjade group) were included in the final analysis. At baseline, in the Osveral vs Exjade group, the mean age was 24.1 vs 22.5 years, respectively, the mean baseline serum ferritin levels were 1772.4 ng/mL vs 2002.8 ng/mL, and the mean transfused blood volume per month was 668.7 mL vs 661.4 mL.

After 6 months, both drugs decreased mean serum ferritin levels significantly from baseline (P <.01). Mean cardiac magnetic resonance imaging T2* scores and mean liver magnetic resonance imaging T2* scores improved in both groups, with no difference noted between the study groups (P =.43 and P =.1, respectively).

“Osveral® can be a suitable cost-effective and a good alternative for Exjade® in Iranian patients with major [beta]-thalassemia,” the authors wrote in their report.


Rafati M, Karami H, Lashtoo-Aghaee B, Lashtoo-Aghaee B, Dabirian M, Avan R. Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial. Caspian J Intern Med. 2022;13(1):61-69. doi:10.22088/cjim.13.1.61